Experience with cetuximab plus paclitaxel/carboplatinum in primary platinum-resistant recurrent head and neck cancer
6077 Background: In patients with platinum-resistant recurrent head and neck cancer the Anti-EGF-receptor antibody cetuximab could be used as a treatment option. Little is known about results of this therapeutic option. The objective of this study was to evaluate therapeutic benefit of this indication. Methods: 23 patients with histological confirmed recurrent head and neck cancer (18 male, 3 female, median age was 57 years) were included in this exploratory study. All recurrences had occurred after chemotherapy with platinum- derivates. 19 patients received radiation therapy during primary treatment. No surgical or radiotherapeutic option in recurrent disease was possible. Two patients were diagnosed with lung metastasis. The 2nd-line therapy consisted of carboplatinum (200 mg/m2) + paclitaxel (200 mg/m2) every three weeks (week 1, 4, and 7) and additionally cetuximab, which was given with 400 mg/m2 as loading dose in week 1 and 250 mg/m2 in week 2–6. Results: A significant tumor response was observed in 13/23 patients (56%). 7 partial, 5 minor and one complete remission were registered. The median survival time was 8 month (range 3–10), 4 patients are still alive. Median time to progression was 5 month (range 2–8). Side effects were rash (16/22), fever (9/22) and typical chemotherapy induced toxicities as neuropathy (7/22) and cytopenia (4/22). All side effects were moderate and easy to handle. Conclusions: The described combined chemoimmuntherapy with cetuximab and paclitaxel + carboplatinum seems to offer new strategies in 2nd and 3rd line chemotherapy for patients with platinum-resistant head and neck cancer, potentially overcoming primary platinum resistance. No significant financial relationships to disclose.